<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>肿瘤资讯 | wechat-feeds</title><link>http://MjM5Nzc4MDk2MA.favicon.privacyhide.com/favicon.ico</link><description>分享肿瘤领域最新进展，传播正确肿瘤防治理念，提高全社会对肿瘤的关注！新浪微博：@肿瘤资讯</description><managingEditor> (hellodword)</managingEditor><pubDate>Tue, 06 Apr 2021 21:29:28 +0800</pubDate><image><url>http://MjM5Nzc4MDk2MA.favicon.privacyhide.com/favicon.ico</url><title>肿瘤资讯 | wechat-feeds</title><link>http://MjM5Nzc4MDk2MA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>【2788】春暖有日，花开有时丨沈琳教授：阿伐替尼中国获批，精准诊疗造福更多胃肠间质瘤患者</title><link>https://mp.weixin.qq.com/s/sn4eleY91OoFz7hwHWemLQ</link><description></description><content:encoded><![CDATA[【2788】春暖有日，花开有时丨沈琳教授：阿伐替尼中国获批，精准诊疗造福更多胃肠间质瘤患者]]></content:encoded><pubDate>Tue, 06 Apr 2021 19:15:22 +0800</pubDate></item><item><title>【专家访谈】陈元教授与张红梅教授共话NSCLC精准免疫治疗策略及irAE管理</title><link>https://mp.weixin.qq.com/s/UHWmQSYZXzl0IWcbwgTSjg</link><description></description><content:encoded><![CDATA[【专家访谈】陈元教授与张红梅教授共话NSCLC精准免疫治疗策略及irAE管理]]></content:encoded><pubDate>Tue, 06 Apr 2021 19:15:22 +0800</pubDate></item><item><title>徐兵河教授：新一代微管抑制剂优替德隆获批上市，为晚期乳腺癌患者化疗带来了新希望</title><link>https://mp.weixin.qq.com/s/b069ovll5B23x-TmaVODhA</link><description></description><content:encoded><![CDATA[徐兵河教授：新一代微管抑制剂优替德隆获批上市，为晚期乳腺癌患者化疗带来了新希望]]></content:encoded><pubDate>Tue, 06 Apr 2021 19:15:22 +0800</pubDate></item><item><title>点亮抗癌之路，助力健康中国！张正果教授谈膀胱癌的发病特点和治疗现状</title><link>https://mp.weixin.qq.com/s/sij4fAmds08Nh7Q1uvCVDg</link><description></description><content:encoded><![CDATA[点亮抗癌之路，助力健康中国！张正果教授谈膀胱癌的发病特点和治疗现状]]></content:encoded><pubDate>Tue, 06 Apr 2021 19:15:22 +0800</pubDate></item><item><title>中医肿瘤的病机——脏腑失调</title><link>https://mp.weixin.qq.com/s/6I4MIUeTC2ZlidceYOc3BA</link><description></description><content:encoded><![CDATA[中医肿瘤的病机——脏腑失调]]></content:encoded><pubDate>Tue, 06 Apr 2021 19:15:22 +0800</pubDate></item><item><title>点亮抗癌之路，助力健康中国！吴海虎教授谈二次TURBT在膀胱癌中的应用</title><link>https://mp.weixin.qq.com/s/RCVmtlqVfzehpkKUasP0wg</link><description></description><content:encoded><![CDATA[点亮抗癌之路，助力健康中国！吴海虎教授谈二次TURBT在膀胱癌中的应用]]></content:encoded><pubDate>Tue, 06 Apr 2021 19:15:22 +0800</pubDate></item><item><title>罕见病诊疗之神经纤维瘤病I型（NF-I型）</title><link>https://mp.weixin.qq.com/s/DYcfTfX7kcNb8J8Kd1l_tw</link><description></description><content:encoded><![CDATA[罕见病诊疗之神经纤维瘤病I型（NF-I型）]]></content:encoded><pubDate>Tue, 06 Apr 2021 19:15:22 +0800</pubDate></item><item><title>约8700万人中招！一旦“沾上”务必警觉！</title><link>https://mp.weixin.qq.com/s/l14Vdj9RxHEIG72w-QflLg</link><description></description><content:encoded><![CDATA[约8700万人中招！一旦“沾上”务必警觉！]]></content:encoded><pubDate>Tue, 06 Apr 2021 19:15:22 +0800</pubDate></item><item><title>【2787】【CA Cancer J Clin】胃癌治疗现状和进展之局部胃癌</title><link>https://mp.weixin.qq.com/s/SuinnkAHCAqKFKVgJpOGvg</link><description></description><content:encoded><![CDATA[【2787】【CA Cancer J Clin】胃癌治疗现状和进展之局部胃癌]]></content:encoded><pubDate>Mon, 05 Apr 2021 19:22:26 +0800</pubDate></item><item><title>吴一龙教授谈NSCLC EGFR 20外显子插入突变诊疗现状与进展，Amivantamab机制独特或可带来突破！</title><link>https://mp.weixin.qq.com/s/w4eJ4KRdsWetyZQt6HOmEQ</link><description></description><content:encoded><![CDATA[吴一龙教授谈NSCLC EGFR 20外显子插入突变诊疗现状与进展，Amivantamab机制独特或可带来突破！]]></content:encoded><pubDate>Mon, 05 Apr 2021 19:22:26 +0800</pubDate></item><item><title>【SGO 2021】顺铂+紫杉醇用于卵巢癌中间型减瘤术后腹腔热灌注化疗较顺铂单药改善PFS</title><link>https://mp.weixin.qq.com/s/bMUMuY6WIEhKfOcGzf96MQ</link><description></description><content:encoded><![CDATA[【SGO 2021】顺铂+紫杉醇用于卵巢癌中间型减瘤术后腹腔热灌注化疗较顺铂单药改善PFS]]></content:encoded><pubDate>Mon, 05 Apr 2021 19:22:26 +0800</pubDate></item><item><title>儿童肿瘤精准诊疗协作组正式成立</title><link>https://mp.weixin.qq.com/s/sOZv-Zgw-wNyI671ZFR5aQ</link><description></description><content:encoded><![CDATA[儿童肿瘤精准诊疗协作组正式成立]]></content:encoded><pubDate>Mon, 05 Apr 2021 19:22:26 +0800</pubDate></item><item><title>【2786】JAMA子刊综述丨退而求其次 or 另寻佳径？肺外神经内分泌癌治疗，何去何从？</title><link>https://mp.weixin.qq.com/s/qgrBb3Trmf-CUzjX9WIhgA</link><description></description><content:encoded><![CDATA[【2786】JAMA子刊综述丨退而求其次 or 另寻佳径？肺外神经内分泌癌治疗，何去何从？]]></content:encoded><pubDate>Sun, 04 Apr 2021 19:44:03 +0800</pubDate></item><item><title>【SGO 2021】伊沙匹隆+贝伐珠单抗治疗铂耐药或难治性卵巢/输卵管/原发性腹膜癌PFS/OS双获益</title><link>https://mp.weixin.qq.com/s/L5GFME2AhXG0jQoCoSlNZw</link><description></description><content:encoded><![CDATA[【SGO 2021】伊沙匹隆+贝伐珠单抗治疗铂耐药或难治性卵巢/输卵管/原发性腹膜癌PFS/OS双获益]]></content:encoded><pubDate>Sun, 04 Apr 2021 19:44:03 +0800</pubDate></item><item><title>周俭教授&amp;匡铭教授：FGFR抑制剂Pemigatinib开启晚期肝内胆管癌治疗新征程</title><link>https://mp.weixin.qq.com/s/Y8AvRj9-vS_ay9xfOzUbEw</link><description></description><content:encoded><![CDATA[周俭教授&匡铭教授：FGFR抑制剂Pemigatinib开启晚期肝内胆管癌治疗新征程]]></content:encoded><pubDate>Sun, 04 Apr 2021 19:44:03 +0800</pubDate></item><item><title>【SGO 2021】Ⅰ期高危子宫内膜癌根治性手术后辅助化疗和放疗对复发和生存的影响</title><link>https://mp.weixin.qq.com/s/zlseAkoBHAsaDk32gX0CNA</link><description></description><content:encoded><![CDATA[【SGO 2021】Ⅰ期高危子宫内膜癌根治性手术后辅助化疗和放疗对复发和生存的影响]]></content:encoded><pubDate>Sun, 04 Apr 2021 19:44:03 +0800</pubDate></item><item><title>【中国好声音】替雷利珠单抗荣登JAMA Oncology，中国智造再次闪耀全球！</title><link>https://mp.weixin.qq.com/s/VsK9SMm9am97XS0xY4K3Ag</link><description></description><content:encoded><![CDATA[【中国好声音】替雷利珠单抗荣登JAMA Oncology，中国智造再次闪耀全球！]]></content:encoded><pubDate>Sat, 03 Apr 2021 18:32:09 +0800</pubDate></item><item><title>【开放共赢 精准赋能】罗氏诊断与同宜医药签署战略合作协议，加速肿瘤创新药物伴随诊断研发</title><link>https://mp.weixin.qq.com/s/3yAsx2kJ7EwDprHqnHHsXg</link><description></description><content:encoded><![CDATA[【开放共赢 精准赋能】罗氏诊断与同宜医药签署战略合作协议，加速肿瘤创新药物伴随诊断研发]]></content:encoded><pubDate>Sat, 03 Apr 2021 18:32:09 +0800</pubDate></item><item><title>【SGO 2021】KEYNOTE-158外阴鳞癌队列结果出炉：ORR 10.9%，疗效与PD-L1状态无关</title><link>https://mp.weixin.qq.com/s/jTDYbiPUMQFByiIUpGImXw</link><description></description><content:encoded><![CDATA[【SGO 2021】KEYNOTE-158外阴鳞癌队列结果出炉：ORR 10.9%，疗效与PD-L1状态无关]]></content:encoded><pubDate>Sat, 03 Apr 2021 18:32:09 +0800</pubDate></item><item><title>【SGO 2021】早期宫颈癌患者早产风险增加——一项基于人群的队列研究</title><link>https://mp.weixin.qq.com/s/Y33d-UnchBJopq8XgoQwgA</link><description></description><content:encoded><![CDATA[【SGO 2021】早期宫颈癌患者早产风险增加——一项基于人群的队列研究]]></content:encoded><pubDate>Sat, 03 Apr 2021 18:32:09 +0800</pubDate></item></channel></rss>